
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio Inc., a clinical-stage biopharmaceutical company, has demonstrated a substantial market response with a nearly 500% increase in stock price following the release of the full HARMONi-2 dataset, indicating strong investor sentiment and confidence in its TIL therapies. The company’s DCF analysis suggests a firm value of approximately $884 million, reflecting the potential growth of its autologous tumor infiltrating lymphocyte therapies and the impact of upcoming catalysts within the competitive landscape. Furthermore, Instil Bio is positioned favorably in the market by leveraging innovative approaches that combine checkpoint inhibition with anti-angiogenesis strategies, creating multiple avenues for success in treating various cancer indications.
Bears say
Instil Bio Inc reported a significant increase in its net loss for the fourth quarter of 2024, amounting to $1.82 per share, compared to previous estimates of a loss of $3.65 per share for 2025, projecting a full-year net loss of $11.51 per share. The company faces several key risks that could adversely impact its financial performance, including potential delays in advancing its clinical candidates, the possibility of unfavorable clinical data, particularly for the AXN-2510 therapy in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and risks of medium- to long-term dilution. These factors contribute to an overall negative outlook for the company's financial health and stock performance.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares